Dean Bajorin, MD
Enriched profileEmeritus Member, Memorial Sloan Kettering Cancer Center · Memorial Sloan Kettering Cancer Center
Dean Bajorin is Emeritus Member, Memorial Sloan Kettering Cancer Center at Memorial Sloan Kettering Cancer Center. OpenAlex indexes 863 publications with 52,375 citations (h-index 101); ClinicalTrials.gov lists 19 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Medical Oncology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Dean Bajorin, MD, is Emeritus Member, Memorial Sloan Kettering Cancer Center. The public record shows 863 publications with 52,375 citations (h-index 101), centered on Bladder and Urothelial Cancer Treatments, Urinary and Genital Oncology Studies, Testicular diseases and treatments. It also documents an investigator role on 19 registered clinical trials, industry payments reported by 3 companies, 5 NIH-funded awards (1999–2024).
- Top research focus: Bladder and Urothelial Cancer Treatments
- 19 registered trials on ClinicalTrials.gov
- Open Payments reporting from 3 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 22 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 349.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 19 registered studies on ClinicalTrials.gov. The most recent:
- Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
Sponsor: Memorial Sloan Kettering Cancer Center
- Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy
Sponsor: Memorial Sloan Kettering Cancer Center
- Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer
Sponsor: Memorial Sloan Kettering Cancer Center
Industry payments
Updated 27 Aug 2026
3 companies reported payments to CMS in program years 2021–2023. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year20231 payment
- Merck Sharp & Dohme LLCProgram year20227 payments
- E.R. Squibb & Sons, L.L.C.Program year20211 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Hormonal (systemic)
34.5%l-Thyroxine34.5%Levothyroxine Sodium100%Part D<11 patientsBlood & clotting
22.4%Factor Xa inhibitor22.4%Eliquis100%Part D<11 patientsMetabolism & gastrointestinal
22.4%Serotonin-3 Receptor Antagonist22.4%Ondansetron Hcl100%Part D≥11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
5 NIH research awards on record, funded 1999–2024 per NIH RePORTER. The latest:
- Investigational Cancer Therapeutics Training Program
Sloan-Kettering Inst Can Research
FY2023$759,367T32CA009207
Congress activity
Updated 27 Aug 2026
228 congress contributions (2004–2025) across AACR, ASCO, ASH, ASTRO, ESMO per OpenAlex. The most recent:
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma
New England Journal of Medicine
2021
Most-cited works
by citation count (OpenAlex)- 01Tumor mutational load predicts survival after immunotherapy across multiple cancer typesArticle4,411 citations2019
- 02
- 03Pembrolizumab as Second-Line Therapy for Advanced Urothelial CarcinomaArticle3,420 citations2017
- 04Comprehensive molecular characterization of urothelial bladder carcinomaArticle3,068 citations2014
- 05
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/dean-bajorin-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Dean-F-Bajorin-39952331
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Other
bcan.org/staff/dean-f-bajorin-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bcan.org ↗ - Other
society.asco.org/people/dean-f-bajorin-md-fasco
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →society.asco.org ↗ - Spotify
open.spotify.com/episode/6fWMdxSb8AuXJTosb2ArOX
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →open.spotify.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- Co-chair (former)
National Cancer Institute's Bladder Cancer Task Force
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →giantsofcancercare.com ↗ - Chair (twice)
ASCO Genitourinary Scientific Committee
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →giantsofcancercare.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →giantsofcancercare.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →giantsofcancercare.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
Media & interviews
press, podcasts and appearances- Guest
"The Uromigos: Legends of GU Oncology" podcast episode featuring Dean Bajorin
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cancerhistoryproject.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Valerie Rusch, MD
Memorial Sloan Kettering Cancer Center
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center